TICH 2 Trial
Tranexamic Acid for Hyperacute Primary IntraCerebral Haemorrhage
To assess whether tranexamic acid is safe and reduces death and dependency after hyperacute (within 8 hours of onset) spontaneous intracerebral haemorrhage.
A phase III prospective pragmatic double blind randomised placebo controlled trial
Dr Nikola Sprigg (Medical expert) Clinical Associate Professor, University of Nottingham
Professor Rustam Al-Shahi Salman, Professor of clinical neurology, University of Edinburgh & NHS Lothian
Local lead in ED
Dr Matt Reed is the local contact for recruitment of ED patients into the study.
- EMERGE Research team
- Stroke Research Group
Eligibility criteria (summary)
Patients who present to the ED within 8 hours of acute spontaneous intracerebral haemorrhagic stroke.
For more information please refer to main trial website